The first PROTAC is here. What comes next in protein degradation?
From Beyond Biotech - the podcast from Labiotech · · 35 min
This plays from the publisher's own server. We do not host a copy.
Description
Today I'm sitting down with Randy Teel, Ph.D., President and CEO of Arvinas, a clinical-stage biotech based in New Haven, Connecticut, that is doing something genuinely new in medicine.
Arvinas is pioneering a technology called PROTAC protein degradation. It's a platform that doesn't just block disease-causing proteins, but eliminates them entirely using the body's own disposal system to do it. It's a fundamental shift in how we think about drug design, and it's now reached a historic milestone: the first PROTAC ever to succeed in a Phase 3 clinical trial, with a regulatory filing now in front of the FDA.
- 01:19 Meet Randy Teel
- 03:41 Stepping into the CEO role in February 2026
- 13:17 What is a PROTAC and how it works
- 17:37 Vepdegestrant and the first PROTAC approval
- 23:43 Balancing partnerships versus keeping control of assets
- 31:57 Key milestones to watch in the next 12–18 months
Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! (https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&utm_medium=podcast_description&utm_source=podcast)
Stay updated by subscribing to our newsletter (https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&utm_medium=podcast_description&utm_source=podcast)
To dive deeper into the topic:
- From undruggable to oral therapy: The rise of STAT6 degraders (https://www.labiotech.eu/in-depth/stat6-degraders/)
- Big Pharma Strikes Megadeals In Targeted Protein Degradation (https://www.labiotech.eu/trends-news/protein-degradation-dunad/)
- This Biotech Destroys Cancer Proteins by Introducing Them to ‘Executioner’ Proteins (https://www.labiotech.eu/startup-scout/polyprox-protacs-cancer-treatment/)
Back to Beyond Biotech - the podcast from Labiotech · Report a problem